Disease Activity and Maternal–fetal Outcomes in Pregnant Women With Prolactinoma: A Systematic Review and Meta-analysis
Authors' conclusion
Pregnancy in women with prolactinoma is safe in relation to fetal and maternal outcomes with low frequencies of miscarriage, prematurity, symptomatic growth, visual impairment, headache, congenital malformations, perinatal mortality, and low birth weight.
Study context
- Population
- Pregnant women with prolactinoma; observational studies including at least 3 pregnant women with prolactinoma
- Participants
- 1,928 women52 studies2,544 pregnancies
- Outcome
- Maternal-fetal outcomes and disease activity during pregnancy (pooled frequency)
Methodological detailsproportional meta-analyses, Sources: MEDLINE, EMBASE, LILACS, CENTRAL, Two independent reviewers selected studies, assessed risk of bias and extracted data
- Proportional meta-analyses
- Sources: MEDLINE, EMBASE, LILACS, CENTRAL
- Two independent reviewers selected studies, assessed risk of bias and extracted data
Pooled result
As reported in the abstract
- Miscarriage
- 10% (95% CI, 8-12)
- Prematurity
- 3% (95% CI, 2-5)
- Symptomatic tumor growth during pregnancy
- 4% (95% CI, 2-8)
- Visual impairment
- 4% (95% CI, 2-7)
- Headache
- 6% (95% CI, 4-9)
- GDM
- 4% (95% CI, 3-7)
- Congenital malformations
- 2% (95% CI, 1-4)
- Perinatal mortality
- 2% (95% CI, 1-2)
- Low birth weight
- 6% (95% CI, 3-9)
Further pooled results
Dopamine agonist treatment
- On dopamine agonist at conception
- 97%
- Continuing or resuming treatment during pregnancy
- 6%
Modifier of visual impairment
- Prolactinoma size is a significant modifier for visual impairment
Original publication
Disease Activity and Maternal–fetal Outcomes in Pregnant Women With Prolactinoma: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. Published 25 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →